Nalaganje...

Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success

PURPOSE: Agents targeting HR-positive, HER2-negative locally advanced or metastatic breast cancer have improved patient outcomes compared with conventional single-agent endocrine therapy. Currently, approved targeted agents include everolimus and three CDK4/6 inhibitors, palbociclib, ribociclib, and...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Breast Cancer Res Treat
Main Authors: Cazzaniga, Marina Elena, Danesi, Romano, Girmenia, Corrado, Invernizzi, Pietro, Elvevi, Alessandra, Uguccioni, Massimo
Format: Artigo
Jezik:Inglês
Izdano: Springer US 2019
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6586706/
https://ncbi.nlm.nih.gov/pubmed/31065872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-019-05261-5
Oznake: Označite
Brez oznak, prvi označite!